AET,Aetna second-quarter profit rises after Coventry acquisitionREFILE-US STOCKS-Futures tick higher before data, Fed in focusUS STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.    US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.     US STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.    US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.    * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.    US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.      REFILE-US STOCKS-Futures tick higher before data, Fed in focusUS STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.    US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.     US STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.    US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.    * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.    US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.     July 30 U.S. health insurer Aetna Inc on Tuesday reported higher second-quarter earnings and revenue, helped by its acquisition of Coventry Health Care and by medical costs that remained low.REFILE-US STOCKS-Futures tick higher before data, Fed in focusUS STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.    US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.     US STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.    US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.    * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.    US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.   US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.  UPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care. * Mosaic, Potash Corp sink after Russia quits top potash cartelUPDATE 3-Aetna profit rises as medical costs stay low July 30 U.S. health insurer Aetna Inc  reported higher quarterly profits on Tuesday as medical costs in its employer-based and commercial business remained low and it closed on its acquisition of Coventry Health Care.      
AFL,Insurer Aflac's profit rises 84 pctUPDATE 1-Insurer Aflac's profit rises on strong sales in Japan * Expects 3rd-qtr profit/share $1.41-$1.51 vs. est. $1.53  UPDATE 1-Insurer Aflac's profit rises on strong sales in Japan * Expects 3rd-qtr profit/share $1.41-$1.51 vs. est. $1.53 July 30 Life insurer Aflac Inc reported a 84 percent rise in second-quarter profit, helped by strong revenue growth in its Japanese unit.UPDATE 1-Insurer Aflac's profit rises on strong sales in Japan * Expects 3rd-qtr profit/share $1.41-$1.51 vs. est. $1.53  
ALXN,Alexion shares rise after report of approach by Roche July 30 Shares of Alexion Pharmaceuticals Inc  rose more than 7 percent on Tuesday following a report that Swiss drugmaker Roche Holding AG made an informal approach to the biotech company last week about a takeover. 
AMGN,Amgen profit ex-items tops Wall Street view; rebounds after 1st qtrAmgen profit tops Wall Street view; rebounds from first quarterUPDATE 2-Amgen profit tops Wall Street view; rebounds from 1st qtr July 30 Amgen Inc, which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its medicines rebounded from a disappointing first quarter.  UPDATE 2-Amgen profit tops Wall Street view; rebounds from 1st qtr July 30 Amgen Inc, which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its medicines rebounded from a disappointing first quarter. Amgen Inc , which is attempting to buy Onyx Pharmaceuticals Inc  to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its drugs rebounded from a disappointing first quarter.UPDATE 2-Amgen profit tops Wall Street view; rebounds from 1st qtr July 30 Amgen Inc, which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its medicines rebounded from a disappointing first quarter.   Amgen profit tops Wall Street view; rebounds from first quarterUPDATE 2-Amgen profit tops Wall Street view; rebounds from 1st qtr July 30 Amgen Inc, which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its medicines rebounded from a disappointing first quarter.  UPDATE 2-Amgen profit tops Wall Street view; rebounds from 1st qtr July 30 Amgen Inc, which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its medicines rebounded from a disappointing first quarter. Amgen Inc , which is attempting to buy Onyx Pharmaceuticals Inc  to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its drugs rebounded from a disappointing first quarter.UPDATE 2-Amgen profit tops Wall Street view; rebounds from 1st qtr July 30 Amgen Inc, which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its medicines rebounded from a disappointing first quarter.  July 30 Amgen Inc, which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its drugs rebounded from a disappointing first quarter.Amgen profit tops Wall Street view; rebounds from first quarterUPDATE 2-Amgen profit tops Wall Street view; rebounds from 1st qtr July 30 Amgen Inc, which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its medicines rebounded from a disappointing first quarter.  UPDATE 2-Amgen profit tops Wall Street view; rebounds from 1st qtr July 30 Amgen Inc, which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its medicines rebounded from a disappointing first quarter. Amgen Inc , which is attempting to buy Onyx Pharmaceuticals Inc  to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its drugs rebounded from a disappointing first quarter.UPDATE 2-Amgen profit tops Wall Street view; rebounds from 1st qtr July 30 Amgen Inc, which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its medicines rebounded from a disappointing first quarter.   
BA,U.S. regulators order foreign airlines to use automatic landing at San FranciscoJapan's ANA says to buy 3 Boeing 777s and one 767 aircraftJapan's ANA says to buy 3 Boeing 777s and one 767 aircraft TOKYO All Nippon Airways  said on Tuesday it will buy three Boeing Co  777-300ER jets and one 767 cargo aircraft, with the orders worth $1.13 billion based on the airplane maker's list price.  Japan's ANA says to buy 3 Boeing 777s and one 767 aircraft TOKYO All Nippon Airways  said on Tuesday it will buy three Boeing Co  777-300ER jets and one 767 cargo aircraft, with the orders worth $1.13 billion based on the airplane maker's list price. TOKYO, July 30 All Nippon Airways said on Tuesday it will buy three Boeing Co 777-300ER jets and one 767 cargo aircraft, with the orders worth $1.13 billion based on the airplane maker's list price.Japan's ANA says to buy 3 Boeing 777s and one 767 aircraft TOKYO All Nippon Airways  said on Tuesday it will buy three Boeing Co  777-300ER jets and one 767 cargo aircraft, with the orders worth $1.13 billion based on the airplane maker's list price.   Japan's ANA says to buy 3 Boeing 777s and one 767 aircraftJapan's ANA says to buy 3 Boeing 777s and one 767 aircraft TOKYO All Nippon Airways  said on Tuesday it will buy three Boeing Co  777-300ER jets and one 767 cargo aircraft, with the orders worth $1.13 billion based on the airplane maker's list price.  Japan's ANA says to buy 3 Boeing 777s and one 767 aircraft TOKYO All Nippon Airways  said on Tuesday it will buy three Boeing Co  777-300ER jets and one 767 cargo aircraft, with the orders worth $1.13 billion based on the airplane maker's list price. TOKYO, July 30 All Nippon Airways said on Tuesday it will buy three Boeing Co 777-300ER jets and one 767 cargo aircraft, with the orders worth $1.13 billion based on the airplane maker's list price.Japan's ANA says to buy 3 Boeing 777s and one 767 aircraft TOKYO All Nippon Airways  said on Tuesday it will buy three Boeing Co  777-300ER jets and one 767 cargo aircraft, with the orders worth $1.13 billion based on the airplane maker's list price.  SINGAPORE, July 30 U.S. aviation regulators have mandated that foreign airlines must use automatic landing aids, instead of visual cues, when approaching San Francisco International Airport where an Asiana Airlines  Boeing Co 777 crashed last month.Japan's ANA says to buy 3 Boeing 777s and one 767 aircraftJapan's ANA says to buy 3 Boeing 777s and one 767 aircraft TOKYO All Nippon Airways  said on Tuesday it will buy three Boeing Co  777-300ER jets and one 767 cargo aircraft, with the orders worth $1.13 billion based on the airplane maker's list price.  Japan's ANA says to buy 3 Boeing 777s and one 767 aircraft TOKYO All Nippon Airways  said on Tuesday it will buy three Boeing Co  777-300ER jets and one 767 cargo aircraft, with the orders worth $1.13 billion based on the airplane maker's list price. TOKYO, July 30 All Nippon Airways said on Tuesday it will buy three Boeing Co 777-300ER jets and one 767 cargo aircraft, with the orders worth $1.13 billion based on the airplane maker's list price.Japan's ANA says to buy 3 Boeing 777s and one 767 aircraft TOKYO All Nippon Airways  said on Tuesday it will buy three Boeing Co  777-300ER jets and one 767 cargo aircraft, with the orders worth $1.13 billion based on the airplane maker's list price.   
CBS,CBS, Time Warner Cable extend fee talks into eveningRobin Williams brings 'Crazy' moments to new CBS showRobin Williams brings 'Crazy' moments to new CBS showUPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.    UPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   LOS ANGELES The freewheeling improvised comedy that made Robin Williams a star on 1970s sitcom "Mork & Mindy" will be on display in his new CBS comedy "The Crazy Ones," though the actor says the series will deliver a character that audiences relate to.UPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.     Robin Williams brings 'Crazy' moments to new CBS showUPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.    UPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   LOS ANGELES The freewheeling improvised comedy that made Robin Williams a star on 1970s sitcom "Mork & Mindy" will be on display in his new CBS comedy "The Crazy Ones," though the actor says the series will deliver a character that audiences relate to.UPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.    LOS ANGELES, July 29 The freewheeling improvised comedy that made Robin Williams a star on 1970s sitcom "Mork & Mindy" will be on display in his new CBS comedy "The Crazy Ones," though the actor says the series will deliver a character that audiences relate to.Robin Williams brings 'Crazy' moments to new CBS showUPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.    UPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   LOS ANGELES The freewheeling improvised comedy that made Robin Williams a star on 1970s sitcom "Mork & Mindy" will be on display in his new CBS comedy "The Crazy Ones," though the actor says the series will deliver a character that audiences relate to.UPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.      Robin Williams brings 'Crazy' moments to new CBS showRobin Williams brings 'Crazy' moments to new CBS showUPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.    UPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   LOS ANGELES The freewheeling improvised comedy that made Robin Williams a star on 1970s sitcom "Mork & Mindy" will be on display in his new CBS comedy "The Crazy Ones," though the actor says the series will deliver a character that audiences relate to.UPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.     Robin Williams brings 'Crazy' moments to new CBS showUPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.    UPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   LOS ANGELES The freewheeling improvised comedy that made Robin Williams a star on 1970s sitcom "Mork & Mindy" will be on display in his new CBS comedy "The Crazy Ones," though the actor says the series will deliver a character that audiences relate to.UPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.    LOS ANGELES, July 29 The freewheeling improvised comedy that made Robin Williams a star on 1970s sitcom "Mork & Mindy" will be on display in his new CBS comedy "The Crazy Ones," though the actor says the series will deliver a character that audiences relate to.Robin Williams brings 'Crazy' moments to new CBS showUPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.    UPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   LOS ANGELES The freewheeling improvised comedy that made Robin Williams a star on 1970s sitcom "Mork & Mindy" will be on display in his new CBS comedy "The Crazy Ones," though the actor says the series will deliver a character that audiences relate to.UPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.     July 29 Time Warner Cable and CBS Corp  have extended their negotiations in a battle over fees the cable company pays to carry the broadcast network, both sides said on Monday.Robin Williams brings 'Crazy' moments to new CBS showRobin Williams brings 'Crazy' moments to new CBS showUPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.    UPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   LOS ANGELES The freewheeling improvised comedy that made Robin Williams a star on 1970s sitcom "Mork & Mindy" will be on display in his new CBS comedy "The Crazy Ones," though the actor says the series will deliver a character that audiences relate to.UPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.     Robin Williams brings 'Crazy' moments to new CBS showUPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.    UPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   LOS ANGELES The freewheeling improvised comedy that made Robin Williams a star on 1970s sitcom "Mork & Mindy" will be on display in his new CBS comedy "The Crazy Ones," though the actor says the series will deliver a character that audiences relate to.UPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.    LOS ANGELES, July 29 The freewheeling improvised comedy that made Robin Williams a star on 1970s sitcom "Mork & Mindy" will be on display in his new CBS comedy "The Crazy Ones," though the actor says the series will deliver a character that audiences relate to.Robin Williams brings 'Crazy' moments to new CBS showUPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.    UPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   LOS ANGELES The freewheeling improvised comedy that made Robin Williams a star on 1970s sitcom "Mork & Mindy" will be on display in his new CBS comedy "The Crazy Ones," though the actor says the series will deliver a character that audiences relate to.UPDATE 1-'Difficult' talks ongoing with Time Warner Cable -CBS CEO Moonves'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.   'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  LOS ANGELES, July 29 CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc  ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.'Difficult' talks ongoing with Time Warner Cable: CBS CEO MoonvesUPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.  UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement. LOS ANGELES CBS Corp Chief Executive Leslie Moonves said on Monday he remained engaged in "difficult" negotiations with Time Warner Cable Inc ahead of a deadline to agree on fees the cable company pays to carry the broadcast network.UPDATE 3-Time Warner Cable teases CBS with blackout; then retreats July 30 Time Warner Cable Inc has agreed to keep the CBS network on the air in New York and Los Angeles until the end of the week after it briefly blacked out CBS's stations in some areas on Tuesday when the two sides failed to reach an agreement.      
COH,Coach comparable sales fall in North America; 2 executives leaveCoach sees soft North America sales; more executives exitUPDATE 4-Coach sees soft North American sales; more executives exit July 30 Coach Inc disclosed a new round of executive departures on Tuesday and reported disappointing handbag sales in North America, dashing investor hopes that the leather goods maker will rebound anytime soon.  UPDATE 4-Coach sees soft North American sales; more executives exit July 30 Coach Inc disclosed a new round of executive departures on Tuesday and reported disappointing handbag sales in North America, dashing investor hopes that the leather goods maker will rebound anytime soon. Disappointing handbag sales in North America last quarter and more change to top management announced on Tuesday hit investors' confidence in the prospects of leather goods maker Coach Inc .UPDATE 4-Coach sees soft North American sales; more executives exit July 30 Coach Inc disclosed a new round of executive departures on Tuesday and reported disappointing handbag sales in North America, dashing investor hopes that the leather goods maker will rebound anytime soon.   Coach sees soft North America sales; more executives exitUPDATE 4-Coach sees soft North American sales; more executives exit July 30 Coach Inc disclosed a new round of executive departures on Tuesday and reported disappointing handbag sales in North America, dashing investor hopes that the leather goods maker will rebound anytime soon.  UPDATE 4-Coach sees soft North American sales; more executives exit July 30 Coach Inc disclosed a new round of executive departures on Tuesday and reported disappointing handbag sales in North America, dashing investor hopes that the leather goods maker will rebound anytime soon. Disappointing handbag sales in North America last quarter and more change to top management announced on Tuesday hit investors' confidence in the prospects of leather goods maker Coach Inc .UPDATE 4-Coach sees soft North American sales; more executives exit July 30 Coach Inc disclosed a new round of executive departures on Tuesday and reported disappointing handbag sales in North America, dashing investor hopes that the leather goods maker will rebound anytime soon.  July 30 Leather goods maker and retailer Coach Inc on Tuesday reported weak sales in North America and the departures of the its chief operating officer and the head of its North American business.Coach sees soft North America sales; more executives exitUPDATE 4-Coach sees soft North American sales; more executives exit July 30 Coach Inc disclosed a new round of executive departures on Tuesday and reported disappointing handbag sales in North America, dashing investor hopes that the leather goods maker will rebound anytime soon.  UPDATE 4-Coach sees soft North American sales; more executives exit July 30 Coach Inc disclosed a new round of executive departures on Tuesday and reported disappointing handbag sales in North America, dashing investor hopes that the leather goods maker will rebound anytime soon. Disappointing handbag sales in North America last quarter and more change to top management announced on Tuesday hit investors' confidence in the prospects of leather goods maker Coach Inc .UPDATE 4-Coach sees soft North American sales; more executives exit July 30 Coach Inc disclosed a new round of executive departures on Tuesday and reported disappointing handbag sales in North America, dashing investor hopes that the leather goods maker will rebound anytime soon.   
GLW,Corning revenue rises on Gorilla Glass sales July 30 Gorilla Glass maker Corning Inc  reported a 4 percent increase in quarterly revenue as demand rose for the scratch-resistant glass used in smartphones and tablets. 
DISCA,Discovery's profit, revenue rise in second quarterDiscovery's profit misses estimates on higher U.S. costsUPDATE 3-Oprah Winfrey Network finally making money for Discovery July 30 The Oprah Winfrey Network is making money four years after its debut, as stronger ratings and advertising growth helped turn around the joint venture with Discovery Communications Inc sooner than expected.  UPDATE 3-Oprah Winfrey Network finally making money for Discovery July 30 The Oprah Winfrey Network is making money four years after its debut, as stronger ratings and advertising growth helped turn around the joint venture with Discovery Communications Inc sooner than expected. Discovery Communications Inc's  second-quarter profit missed analyst estimates on Tuesday as it recorded higher operating expenses at its U.S. cable unit.UPDATE 3-Oprah Winfrey Network finally making money for Discovery July 30 The Oprah Winfrey Network is making money four years after its debut, as stronger ratings and advertising growth helped turn around the joint venture with Discovery Communications Inc sooner than expected.   Discovery's profit misses estimates on higher U.S. costsUPDATE 3-Oprah Winfrey Network finally making money for Discovery July 30 The Oprah Winfrey Network is making money four years after its debut, as stronger ratings and advertising growth helped turn around the joint venture with Discovery Communications Inc sooner than expected.  UPDATE 3-Oprah Winfrey Network finally making money for Discovery July 30 The Oprah Winfrey Network is making money four years after its debut, as stronger ratings and advertising growth helped turn around the joint venture with Discovery Communications Inc sooner than expected. Discovery Communications Inc's  second-quarter profit missed analyst estimates on Tuesday as it recorded higher operating expenses at its U.S. cable unit.UPDATE 3-Oprah Winfrey Network finally making money for Discovery July 30 The Oprah Winfrey Network is making money four years after its debut, as stronger ratings and advertising growth helped turn around the joint venture with Discovery Communications Inc sooner than expected.  July 30 Discovery Communications Inc's  revenue and profit rose in the second quarter, as it posted higher revenue in U.S. advertising and at its international network.Discovery's profit misses estimates on higher U.S. costsUPDATE 3-Oprah Winfrey Network finally making money for Discovery July 30 The Oprah Winfrey Network is making money four years after its debut, as stronger ratings and advertising growth helped turn around the joint venture with Discovery Communications Inc sooner than expected.  UPDATE 3-Oprah Winfrey Network finally making money for Discovery July 30 The Oprah Winfrey Network is making money four years after its debut, as stronger ratings and advertising growth helped turn around the joint venture with Discovery Communications Inc sooner than expected. Discovery Communications Inc's  second-quarter profit missed analyst estimates on Tuesday as it recorded higher operating expenses at its U.S. cable unit.UPDATE 3-Oprah Winfrey Network finally making money for Discovery July 30 The Oprah Winfrey Network is making money four years after its debut, as stronger ratings and advertising growth helped turn around the joint venture with Discovery Communications Inc sooner than expected.   
DISCK,Discovery's profit, revenue rise in second quarterDiscovery's profit misses estimates on higher U.S. costsUPDATE 3-Oprah Winfrey Network finally making money for Discovery July 30 The Oprah Winfrey Network is making money four years after its debut, as stronger ratings and advertising growth helped turn around the joint venture with Discovery Communications Inc sooner than expected.  UPDATE 3-Oprah Winfrey Network finally making money for Discovery July 30 The Oprah Winfrey Network is making money four years after its debut, as stronger ratings and advertising growth helped turn around the joint venture with Discovery Communications Inc sooner than expected. Discovery Communications Inc's  second-quarter profit missed analyst estimates on Tuesday as it recorded higher operating expenses at its U.S. cable unit.UPDATE 3-Oprah Winfrey Network finally making money for Discovery July 30 The Oprah Winfrey Network is making money four years after its debut, as stronger ratings and advertising growth helped turn around the joint venture with Discovery Communications Inc sooner than expected.   Discovery's profit misses estimates on higher U.S. costsUPDATE 3-Oprah Winfrey Network finally making money for Discovery July 30 The Oprah Winfrey Network is making money four years after its debut, as stronger ratings and advertising growth helped turn around the joint venture with Discovery Communications Inc sooner than expected.  UPDATE 3-Oprah Winfrey Network finally making money for Discovery July 30 The Oprah Winfrey Network is making money four years after its debut, as stronger ratings and advertising growth helped turn around the joint venture with Discovery Communications Inc sooner than expected. Discovery Communications Inc's  second-quarter profit missed analyst estimates on Tuesday as it recorded higher operating expenses at its U.S. cable unit.UPDATE 3-Oprah Winfrey Network finally making money for Discovery July 30 The Oprah Winfrey Network is making money four years after its debut, as stronger ratings and advertising growth helped turn around the joint venture with Discovery Communications Inc sooner than expected.  July 30 Discovery Communications Inc's  revenue and profit rose in the second quarter, as it posted higher revenue in U.S. advertising and at its international network.Discovery's profit misses estimates on higher U.S. costsUPDATE 3-Oprah Winfrey Network finally making money for Discovery July 30 The Oprah Winfrey Network is making money four years after its debut, as stronger ratings and advertising growth helped turn around the joint venture with Discovery Communications Inc sooner than expected.  UPDATE 3-Oprah Winfrey Network finally making money for Discovery July 30 The Oprah Winfrey Network is making money four years after its debut, as stronger ratings and advertising growth helped turn around the joint venture with Discovery Communications Inc sooner than expected. Discovery Communications Inc's  second-quarter profit missed analyst estimates on Tuesday as it recorded higher operating expenses at its U.S. cable unit.UPDATE 3-Oprah Winfrey Network finally making money for Discovery July 30 The Oprah Winfrey Network is making money four years after its debut, as stronger ratings and advertising growth helped turn around the joint venture with Discovery Communications Inc sooner than expected.   
EBAY,UPDATE 1-SoftBank on course for record profit, expanding online empire * Softbank forecasts record 1 trln yen oper profit for year to March 2014 
ETR,UPDATE 1-Entergy to cut jobs, mulls future of wholesale nuclear * Entergy, ITC work to complete transmission asset transfer 
EQR,UPDATE 2-Equity Residential 2nd-quarter profit meets Wall St forecast NEW YORK, July 30 Apartment owner Equity Residential said on Tuesday that  a profit measure used for real estate investment trusts rose in the second quarter, helped in part by higher rent and its Archstone acquisition. 
FB,US STOCKS-S&P; 500, Nasdaq end up as tech gains; potash shares sink * Mosaic, Potash Corp sink after Russia quits top potash cartel 
FLR,UPDATE 2-CB&I; profit tops estimates, but order outlook tempered July 30 Engineering company Chicago Bridge & Iron Co NV reported on Tuesday a higher-than-expected quarterly profit, but revised lower its anticipated new orders this year. 
GM,CORRECTED-GM to debut new Spark in 2015, delays Aveo launch - Korean unionPeugeot bailout gets EU green light PARIS/BRUSSELS PSA Peugeot Citroen  won EU approval for a 7 billion euro ($9.28 billion) state-backed debt rescue, keeping the French automaker afloat as it struggles to rein in losses.  Peugeot bailout gets EU green light PARIS/BRUSSELS PSA Peugeot Citroen  won EU approval for a 7 billion euro ($9.28 billion) state-backed debt rescue, keeping the French automaker afloat as it struggles to rein in losses. SEOUL, July 30 General Motors Co plans to launch its next-generation Chevrolet Spark mini car in the first half of 2015, but will delay the launch of its revamped Aveo small car, a South Korean labour union spokesman said on Tuesday.Peugeot bailout gets EU green light PARIS/BRUSSELS PSA Peugeot Citroen  won EU approval for a 7 billion euro ($9.28 billion) state-backed debt rescue, keeping the French automaker afloat as it struggles to rein in losses.  
GT,Goodyear Tire profit tops estimate as demand returns in EuropeGoodyear Tire profit tops estimate as demand returns in EuropeUPDATE 2-Goodyear sees sales stabilizing in Europe; lower costs boost margins * Shares rise as much as 15 pct   (Adds details from conference call, updates share price)  UPDATE 2-Goodyear sees sales stabilizing in Europe; lower costs boost margins * Shares rise as much as 15 pct   (Adds details from conference call, updates share price) Goodyear Tire & Rubber Co's  quarterly profit more than doubled due to lower raw material costs and stabilizing sales in Europe, where many customers have bought new tires for the summer for the first time in years.UPDATE 2-Goodyear sees sales stabilizing in Europe; lower costs boost margins * Shares rise as much as 15 pct   (Adds details from conference call, updates share price)   Goodyear Tire profit tops estimate as demand returns in EuropeUPDATE 2-Goodyear sees sales stabilizing in Europe; lower costs boost margins * Shares rise as much as 15 pct   (Adds details from conference call, updates share price)  UPDATE 2-Goodyear sees sales stabilizing in Europe; lower costs boost margins * Shares rise as much as 15 pct   (Adds details from conference call, updates share price) Goodyear Tire & Rubber Co's  quarterly profit more than doubled due to lower raw material costs and stabilizing sales in Europe, where many customers have bought new tires for the summer for the first time in years.UPDATE 2-Goodyear sees sales stabilizing in Europe; lower costs boost margins * Shares rise as much as 15 pct   (Adds details from conference call, updates share price)  Goodyear Tire & Rubber Co's  quarterly profit more than doubled due to lower raw material costs and stabilizing sales in Europe, where many customers have bought new tires for the summer for the first time in years.Goodyear Tire profit tops estimate as demand returns in EuropeUPDATE 2-Goodyear sees sales stabilizing in Europe; lower costs boost margins * Shares rise as much as 15 pct   (Adds details from conference call, updates share price)  UPDATE 2-Goodyear sees sales stabilizing in Europe; lower costs boost margins * Shares rise as much as 15 pct   (Adds details from conference call, updates share price) Goodyear Tire & Rubber Co's  quarterly profit more than doubled due to lower raw material costs and stabilizing sales in Europe, where many customers have bought new tires for the summer for the first time in years.UPDATE 2-Goodyear sees sales stabilizing in Europe; lower costs boost margins * Shares rise as much as 15 pct   (Adds details from conference call, updates share price)   
JPM,JPMorgan to pay $410 mln in U.S. power market manipulation probeUPDATE 1-JPMorgan to pay $410 mln to settle US power market caseUPDATE 3-JPMorgan to pay $410 mln to settle U.S. power market case NEW YORK, July 30 JPMorgan Chase & Co  agreed on Tuesday to pay $410 million to settle allegations of power market manipulation in California and the Midwest, the latest in a series of high-profile inquiries by U.S. federal energy regulators.  UPDATE 3-JPMorgan to pay $410 mln to settle U.S. power market case NEW YORK, July 30 JPMorgan Chase & Co  agreed on Tuesday to pay $410 million to settle allegations of power market manipulation in California and the Midwest, the latest in a series of high-profile inquiries by U.S. federal energy regulators. July 30 JPMorgan Chase & Co agreed on Tuesday to pay $410 million to settle allegations of power market manipulation in California and the Midwest, the latest in a series of high-profile inquiries by U.S. federal energy regulators.UPDATE 3-JPMorgan to pay $410 mln to settle U.S. power market case NEW YORK, July 30 JPMorgan Chase & Co  agreed on Tuesday to pay $410 million to settle allegations of power market manipulation in California and the Midwest, the latest in a series of high-profile inquiries by U.S. federal energy regulators.   UPDATE 1-JPMorgan to pay $410 mln to settle US power market caseUPDATE 3-JPMorgan to pay $410 mln to settle U.S. power market case NEW YORK, July 30 JPMorgan Chase & Co  agreed on Tuesday to pay $410 million to settle allegations of power market manipulation in California and the Midwest, the latest in a series of high-profile inquiries by U.S. federal energy regulators.  UPDATE 3-JPMorgan to pay $410 mln to settle U.S. power market case NEW YORK, July 30 JPMorgan Chase & Co  agreed on Tuesday to pay $410 million to settle allegations of power market manipulation in California and the Midwest, the latest in a series of high-profile inquiries by U.S. federal energy regulators. July 30 JPMorgan Chase & Co agreed on Tuesday to pay $410 million to settle allegations of power market manipulation in California and the Midwest, the latest in a series of high-profile inquiries by U.S. federal energy regulators.UPDATE 3-JPMorgan to pay $410 mln to settle U.S. power market case NEW YORK, July 30 JPMorgan Chase & Co  agreed on Tuesday to pay $410 million to settle allegations of power market manipulation in California and the Midwest, the latest in a series of high-profile inquiries by U.S. federal energy regulators.  July 30 JPMorgan Chase & Co agreed to pay a civil penalty of $285 million and disgorge $125 million to settle allegations of power market manipulation in California and the Midwest, the latest settlement in a series of high-profile investigations by U.S. federal energy regulators against banks.UPDATE 1-JPMorgan to pay $410 mln to settle US power market caseUPDATE 3-JPMorgan to pay $410 mln to settle U.S. power market case NEW YORK, July 30 JPMorgan Chase & Co  agreed on Tuesday to pay $410 million to settle allegations of power market manipulation in California and the Midwest, the latest in a series of high-profile inquiries by U.S. federal energy regulators.  UPDATE 3-JPMorgan to pay $410 mln to settle U.S. power market case NEW YORK, July 30 JPMorgan Chase & Co  agreed on Tuesday to pay $410 million to settle allegations of power market manipulation in California and the Midwest, the latest in a series of high-profile inquiries by U.S. federal energy regulators. July 30 JPMorgan Chase & Co agreed on Tuesday to pay $410 million to settle allegations of power market manipulation in California and the Midwest, the latest in a series of high-profile inquiries by U.S. federal energy regulators.UPDATE 3-JPMorgan to pay $410 mln to settle U.S. power market case NEW YORK, July 30 JPMorgan Chase & Co  agreed on Tuesday to pay $410 million to settle allegations of power market manipulation in California and the Midwest, the latest in a series of high-profile inquiries by U.S. federal energy regulators.   
KMI,Fitch Affirms Kinder Morgan Inc. and El Paso LLC at 'BB+'; Outlook Stable (The following statement was released by the rating agency) NEW YORK, July 30 (Fitch) Fitch Ratings has affirmed the Issuer Default Ratings  (IDR) for Kinder Morgan, Inc. (KMI) and El Paso LLC (EP, formerly El Paso  Corporation) at 'BB+'. Both KMI and EP have Stable Rating Outlooks. EP is a  wholly-owned subsidiary of KMI and its debt is cross-guaranteed and ratably  secured with KMI. A complete list of KMI and EP ratings follows at the end of this release.  Approximately $5 billion of KMI debt  
LMT,Lockheed, Pentagon set lower-cost F-35 deal that preserves jetsLockheed, Pentagon set lower-cost F-35 deal to allow full order WASHINGTON Lockheed Martin Corp  and the Pentagon on Tuesday said they reached an agreement for 71 more F-35 fighter jets, with lower pricing allowing the U.S. government to buy all the planes it had planned despite budget cuts that took effect in March.  Lockheed, Pentagon set lower-cost F-35 deal to allow full order WASHINGTON Lockheed Martin Corp  and the Pentagon on Tuesday said they reached an agreement for 71 more F-35 fighter jets, with lower pricing allowing the U.S. government to buy all the planes it had planned despite budget cuts that took effect in March. WASHINGTON, July 30 Lockheed Martin Corp  and the Pentagon on Tuesday said they reached an agreement for 71 more F-35 fighter jets, with lower pricing allowing the government to buy all the planes it had planned despite budget cuts that took effect in March.Lockheed, Pentagon set lower-cost F-35 deal to allow full order WASHINGTON Lockheed Martin Corp  and the Pentagon on Tuesday said they reached an agreement for 71 more F-35 fighter jets, with lower pricing allowing the U.S. government to buy all the planes it had planned despite budget cuts that took effect in March.  
MCD,CORRECTED-U.S. fast food workers kick-off multi-city protests for higher payFast food workers kick-off multi-city protests for higher pay Hundreds of low-wage workers at fast-food chains such as McDonald's  and Wendy's on Monday protested in the streets of New York, kick-starting a week of demonstrations in several major cities demanding the right to unionize and pressing for a pay raise to $15 per hour - double the federal minimum wage.  Fast food workers kick-off multi-city protests for higher pay Hundreds of low-wage workers at fast-food chains such as McDonald's  and Wendy's on Monday protested in the streets of New York, kick-starting a week of demonstrations in several major cities demanding the right to unionize and pressing for a pay raise to $15 per hour - double the federal minimum wage. (Corrects 1st paragraph to show workers demand wage increase not minimum wage increase)Fast food workers kick-off multi-city protests for higher pay Hundreds of low-wage workers at fast-food chains such as McDonald's  and Wendy's on Monday protested in the streets of New York, kick-starting a week of demonstrations in several major cities demanding the right to unionize and pressing for a pay raise to $15 per hour - double the federal minimum wage.  
MRK,Merck revenue misses mark as diabetes, arthritis drugs lagUPDATE 2-Merck revenue hit by weak overseas, consumer salesMerck revenues miss mark as diabetes, arthritis drugs lagWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results.  WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results. Merck & Co Inc's quarterly revenue fell short of Wall Street expectations as the stronger dollar cut sales of its consumer and animal health products and hurt results for prescription drugs, including diabetes treatment Januvia.WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results.   Merck revenues miss mark as diabetes, arthritis drugs lagWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results.  WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results. Merck & Co Inc's quarterly revenue fell short of Wall Street expectations as the stronger dollar cut sales of its consumer and animal health products and hurt results for prescription drugs, including diabetes treatment Januvia.WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results.  July 30 Merck & Co Inc's quarterly revenue fell short of  expectations on disappointing results for the company's consumer and animal health products and weak overseas sales of prescription drugs that were slammed by the stronger dollar.Merck revenues miss mark as diabetes, arthritis drugs lagWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results.  WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results. Merck & Co Inc's quarterly revenue fell short of Wall Street expectations as the stronger dollar cut sales of its consumer and animal health products and hurt results for prescription drugs, including diabetes treatment Januvia.WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results.    UPDATE 2-Merck revenue hit by weak overseas, consumer salesMerck revenues miss mark as diabetes, arthritis drugs lagWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results.  WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results. Merck & Co Inc's quarterly revenue fell short of Wall Street expectations as the stronger dollar cut sales of its consumer and animal health products and hurt results for prescription drugs, including diabetes treatment Januvia.WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results.   Merck revenues miss mark as diabetes, arthritis drugs lagWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results.  WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results. Merck & Co Inc's quarterly revenue fell short of Wall Street expectations as the stronger dollar cut sales of its consumer and animal health products and hurt results for prescription drugs, including diabetes treatment Januvia.WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results.  July 30 Merck & Co Inc's quarterly revenue fell short of  expectations on disappointing results for the company's consumer and animal health products and weak overseas sales of prescription drugs that were slammed by the stronger dollar.Merck revenues miss mark as diabetes, arthritis drugs lagWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results.  WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results. Merck & Co Inc's quarterly revenue fell short of Wall Street expectations as the stronger dollar cut sales of its consumer and animal health products and hurt results for prescription drugs, including diabetes treatment Januvia.WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results.   July 30 Merck & Co's quarterly revenue fell short of Wall Street expectations, on lower sales of its consumer health and animal health products and weak growth of its treatments for diabetes and arthritis.UPDATE 2-Merck revenue hit by weak overseas, consumer salesMerck revenues miss mark as diabetes, arthritis drugs lagWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results.  WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results. Merck & Co Inc's quarterly revenue fell short of Wall Street expectations as the stronger dollar cut sales of its consumer and animal health products and hurt results for prescription drugs, including diabetes treatment Januvia.WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results.   Merck revenues miss mark as diabetes, arthritis drugs lagWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results.  WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results. Merck & Co Inc's quarterly revenue fell short of Wall Street expectations as the stronger dollar cut sales of its consumer and animal health products and hurt results for prescription drugs, including diabetes treatment Januvia.WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results.  July 30 Merck & Co Inc's quarterly revenue fell short of  expectations on disappointing results for the company's consumer and animal health products and weak overseas sales of prescription drugs that were slammed by the stronger dollar.Merck revenues miss mark as diabetes, arthritis drugs lagWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results.  WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results. Merck & Co Inc's quarterly revenue fell short of Wall Street expectations as the stronger dollar cut sales of its consumer and animal health products and hurt results for prescription drugs, including diabetes treatment Januvia.WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter July 30 Big Pharma is still relying on belt-tightening to prop up financial results.    
MSFT,UPDATE 1-Accused SAC Capital tipster arrested in CaliforniaUPDATE 2-Accused tipper to SAC hedge fund arrested in insider-trading probeAccused tipper to SAC hedge fund arrested in insider-trading probeMicrosoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report. A securities analyst accused of leaking secret information in 2009 about a potential partnership between Yahoo and Microsoft to an SAC Capital Advisors hedge fund manager and other traders was arrested and charged in California, prosecutors said on Tuesday. |Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report. VideoMicrosoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.   Accused tipper to SAC hedge fund arrested in insider-trading probeMicrosoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report. A securities analyst accused of leaking secret information in 2009 about a potential partnership between Yahoo and Microsoft to an SAC Capital Advisors hedge fund manager and other traders was arrested and charged in California, prosecutors said on Tuesday. |Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report. VideoMicrosoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  July 30 A securities analyst accused of leaking secret information in 2009 about a potential partnership between Yahoo and Microsoft to an SAC Capital Advisors hedge fund manager and other traders was arrested and charged in California, prosecutors said on Tuesday.Accused tipper to SAC hedge fund arrested in insider-trading probeMicrosoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report. A securities analyst accused of leaking secret information in 2009 about a potential partnership between Yahoo and Microsoft to an SAC Capital Advisors hedge fund manager and other traders was arrested and charged in California, prosecutors said on Tuesday. |Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report. VideoMicrosoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.    UPDATE 2-Accused tipper to SAC hedge fund arrested in insider-trading probeAccused tipper to SAC hedge fund arrested in insider-trading probeMicrosoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report. A securities analyst accused of leaking secret information in 2009 about a potential partnership between Yahoo and Microsoft to an SAC Capital Advisors hedge fund manager and other traders was arrested and charged in California, prosecutors said on Tuesday. |Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report. VideoMicrosoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.   Accused tipper to SAC hedge fund arrested in insider-trading probeMicrosoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report. A securities analyst accused of leaking secret information in 2009 about a potential partnership between Yahoo and Microsoft to an SAC Capital Advisors hedge fund manager and other traders was arrested and charged in California, prosecutors said on Tuesday. |Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report. VideoMicrosoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  July 30 A securities analyst accused of leaking secret information in 2009 about a potential partnership between Yahoo and Microsoft to an SAC Capital Advisors hedge fund manager and other traders was arrested and charged in California, prosecutors said on Tuesday.Accused tipper to SAC hedge fund arrested in insider-trading probeMicrosoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report. A securities analyst accused of leaking secret information in 2009 about a potential partnership between Yahoo and Microsoft to an SAC Capital Advisors hedge fund manager and other traders was arrested and charged in California, prosecutors said on Tuesday. |Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report. VideoMicrosoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.   July 30 A securities analyst who passed non-public information about Yahoo and Microsoft  to a portfolio manager at Steven A. Cohen's hedge fund SAC Capital Advisors was arrested in California, federal prosecutors said on Tuesday.UPDATE 2-Accused tipper to SAC hedge fund arrested in insider-trading probeAccused tipper to SAC hedge fund arrested in insider-trading probeMicrosoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report. A securities analyst accused of leaking secret information in 2009 about a potential partnership between Yahoo and Microsoft to an SAC Capital Advisors hedge fund manager and other traders was arrested and charged in California, prosecutors said on Tuesday. |Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report. VideoMicrosoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.   Accused tipper to SAC hedge fund arrested in insider-trading probeMicrosoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report. A securities analyst accused of leaking secret information in 2009 about a potential partnership between Yahoo and Microsoft to an SAC Capital Advisors hedge fund manager and other traders was arrested and charged in California, prosecutors said on Tuesday. |Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report. VideoMicrosoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  July 30 A securities analyst accused of leaking secret information in 2009 about a potential partnership between Yahoo and Microsoft to an SAC Capital Advisors hedge fund manager and other traders was arrested and charged in California, prosecutors said on Tuesday.Accused tipper to SAC hedge fund arrested in insider-trading probeMicrosoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report. A securities analyst accused of leaking secret information in 2009 about a potential partnership between Yahoo and Microsoft to an SAC Capital Advisors hedge fund manager and other traders was arrested and charged in California, prosecutors said on Tuesday. |Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report. VideoMicrosoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.  Microsoft losing money on Surface tablets SEATTLE, July 30 Microsoft Corp's  Surface tablets have yet to make any profit as sputtering sales have been eclipsed by advertising costs and an accounting charge, according to the software company's annual report.    
MS,Deutsche Bank legal, regulatory costs weigh on earningsMorgan Stanley names new Qatar head as deal activity revives DUBAI, July 30 Morgan Stanley has appointed Qatari national Abdulla al-Ansari as the bank's new head in the country, according to an internal memo seen by Reuters, a sign the U.S. bank is positioning itself for a share of rising deal activity from the gas-rich Gulf state.  Morgan Stanley names new Qatar head as deal activity revives DUBAI, July 30 Morgan Stanley has appointed Qatari national Abdulla al-Ansari as the bank's new head in the country, according to an internal memo seen by Reuters, a sign the U.S. bank is positioning itself for a share of rising deal activity from the gas-rich Gulf state. FRANKFURT Deutsche Bank AG  warned on Tuesday it will face hundreds of millions of euros in costs for litigation and compliance with new bank rules after reporting weaker-than-expected second quarter earnings.Morgan Stanley names new Qatar head as deal activity revives DUBAI, July 30 Morgan Stanley has appointed Qatari national Abdulla al-Ansari as the bank's new head in the country, according to an internal memo seen by Reuters, a sign the U.S. bank is positioning itself for a share of rising deal activity from the gas-rich Gulf state.  
NWSA,Murdoch's wife hires new lawyer in divorce case - New York Times July 29 The wife of News Corp Chief Executive Rupert Murdoch, Wendi Murdoch, has switched lawyers in a move signaling that their divorce proceedings could take an acrimonious turn, the New York Times reported on Monday. 
NWS,Murdoch's wife hires new lawyer in divorce case - New York Times July 29 The wife of News Corp Chief Executive Rupert Murdoch, Wendi Murdoch, has switched lawyers in a move signaling that their divorce proceedings could take an acrimonious turn, the New York Times reported on Monday. 
OXY,Occidental revenue rises 3 percent on higher prices, outputOccidental revenue rises 3 percent on higher prices, outputUPDATE 2-Occidental profit misses, break-up plan due later this yearOccidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit.  Occidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit. * Higher U.S. output offset by lower production in ColombiaOccidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit.   UPDATE 2-Occidental profit misses, break-up plan due later this yearOccidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit.  Occidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit. * Higher U.S. output offset by lower production in ColombiaOccidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit.  Occidental Petroleum Corp  posted a 3 percent rise in revenue as the fourth-largest U.S. oil company gained from higher oil and gas prices and increased output.UPDATE 2-Occidental profit misses, break-up plan due later this yearOccidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit.  Occidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit. * Higher U.S. output offset by lower production in ColombiaOccidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit.    Occidental revenue rises 3 percent on higher prices, outputUPDATE 2-Occidental profit misses, break-up plan due later this yearOccidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit.  Occidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit. * Higher U.S. output offset by lower production in ColombiaOccidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit.   UPDATE 2-Occidental profit misses, break-up plan due later this yearOccidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit.  Occidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit. * Higher U.S. output offset by lower production in ColombiaOccidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit.  Occidental Petroleum Corp  posted a 3 percent rise in revenue as the fourth-largest U.S. oil company gained from higher oil and gas prices and increased output.UPDATE 2-Occidental profit misses, break-up plan due later this yearOccidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit.  Occidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit. * Higher U.S. output offset by lower production in ColombiaOccidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit.   July 30 Occidental Petroleum Corp posted a 3 percent rise in revenue as the fourth-largest U.S. oil company gained from higher oil and gas prices and increased output.Occidental revenue rises 3 percent on higher prices, outputUPDATE 2-Occidental profit misses, break-up plan due later this yearOccidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit.  Occidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit. * Higher U.S. output offset by lower production in ColombiaOccidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit.   UPDATE 2-Occidental profit misses, break-up plan due later this yearOccidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit.  Occidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit. * Higher U.S. output offset by lower production in ColombiaOccidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit.  Occidental Petroleum Corp  posted a 3 percent rise in revenue as the fourth-largest U.S. oil company gained from higher oil and gas prices and increased output.UPDATE 2-Occidental profit misses, break-up plan due later this yearOccidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit.  Occidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit. * Higher U.S. output offset by lower production in ColombiaOccidental profit misses, break-up plan due later this year Occidental Petroleum Corp  posted a smaller-than-expected quarterly profit on Tuesday, hurt by lower oil prices in the Middle East and North Africa, where the fourth-largest U.S. oil company is considering an exit.    
OMC,CORRECTED-Merged Publicis-Omnicom may speak with American accent (Corrects quote in last paragraph, replacing 'homogenous' with 'corporate'.) 
PFE,REFILE-US STOCKS-Futures tick higher before data, Fed in focusPfizer earnings top estimates, reiterates forecastUS STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.       US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.        US STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.       US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.       Pfizer Inc reported second-quarter earnings slightly ahead of estimates on Tuesday as the largest U.S. drugmaker lines up a business split that could lead to the spinoff of its generics division.US STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.       US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.         Pfizer earnings top estimates, reiterates forecastUS STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.       US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.        US STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.       US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.       Pfizer Inc reported second-quarter earnings slightly ahead of estimates on Tuesday as the largest U.S. drugmaker lines up a business split that could lead to the spinoff of its generics division.US STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.       US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.        * Mosaic, Potash Corp tumble after Russia quits top potash cartelPfizer earnings top estimates, reiterates forecastUS STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.       US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.        US STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.       US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.       Pfizer Inc reported second-quarter earnings slightly ahead of estimates on Tuesday as the largest U.S. drugmaker lines up a business split that could lead to the spinoff of its generics division.US STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.       US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.      US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.     WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    * Mosaic, Potash Corp sink after Russia quits top potash cartelWRAPUP 1-Cost controls help Pfizer, Merck weather weak quarterCost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.    Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   July 30 Big Pharma is still relying on belt-tightening to prop up financial results.Cost controls help Pfizer, Merck weather weak quarterUPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.   UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Big Pharma is still relying on belt-tightening to prop up financial results.UPDATE 1-Pfizer settles U.S. marketing case related to RapamunePfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.  Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday. WASHINGTON, July 30 Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.Pfizer settles U.S. marketing case related to Rapamune WASHINGTON Pfizer Inc will pay $490.9 million to resolve accusations of illegal marketing of the drug Rapamune dating to Pfizer's 2009 acquisition of Wyeth Pharmaceuticals Inc, the U.S. Justice Department said on Tuesday.         
QCOM,UPDATE 3-Alcatel posts Q2 beat, signs Qualcomm partnershipAlcatel posts strong second-quarter, signs Qualcomm partnershipAlcatel CEO says Qualcomm deal may lead to others PARIS, July 30 Alcatel Lucent's joint venture with Qualcomm could be the first of several deals aimed at boosting the French telecom-equipment maker's footprint in fast-growing technologies, Alcatel's chief executive said on Tuesday.  Alcatel CEO says Qualcomm deal may lead to others PARIS, July 30 Alcatel Lucent's joint venture with Qualcomm could be the first of several deals aimed at boosting the French telecom-equipment maker's footprint in fast-growing technologies, Alcatel's chief executive said on Tuesday. PARIS Struggling telecom equipment maker Alcatel-Lucent surfed on strong growth in its key U.S. market to beat analysts' estimates and said mobile chip maker Qualcomm would buy a minority stake as part of a research partnership.Alcatel CEO says Qualcomm deal may lead to others PARIS, July 30 Alcatel Lucent's joint venture with Qualcomm could be the first of several deals aimed at boosting the French telecom-equipment maker's footprint in fast-growing technologies, Alcatel's chief executive said on Tuesday.   Alcatel posts strong second-quarter, signs Qualcomm partnershipAlcatel CEO says Qualcomm deal may lead to others PARIS, July 30 Alcatel Lucent's joint venture with Qualcomm could be the first of several deals aimed at boosting the French telecom-equipment maker's footprint in fast-growing technologies, Alcatel's chief executive said on Tuesday.  Alcatel CEO says Qualcomm deal may lead to others PARIS, July 30 Alcatel Lucent's joint venture with Qualcomm could be the first of several deals aimed at boosting the French telecom-equipment maker's footprint in fast-growing technologies, Alcatel's chief executive said on Tuesday. PARIS Struggling telecom equipment maker Alcatel-Lucent surfed on strong growth in its key U.S. market to beat analysts' estimates and said mobile chip maker Qualcomm would buy a minority stake as part of a research partnership.Alcatel CEO says Qualcomm deal may lead to others PARIS, July 30 Alcatel Lucent's joint venture with Qualcomm could be the first of several deals aimed at boosting the French telecom-equipment maker's footprint in fast-growing technologies, Alcatel's chief executive said on Tuesday.  * Net loss widens on mobile writedown, cash burn persistsAlcatel posts strong second-quarter, signs Qualcomm partnershipAlcatel CEO says Qualcomm deal may lead to others PARIS, July 30 Alcatel Lucent's joint venture with Qualcomm could be the first of several deals aimed at boosting the French telecom-equipment maker's footprint in fast-growing technologies, Alcatel's chief executive said on Tuesday.  Alcatel CEO says Qualcomm deal may lead to others PARIS, July 30 Alcatel Lucent's joint venture with Qualcomm could be the first of several deals aimed at boosting the French telecom-equipment maker's footprint in fast-growing technologies, Alcatel's chief executive said on Tuesday. PARIS Struggling telecom equipment maker Alcatel-Lucent surfed on strong growth in its key U.S. market to beat analysts' estimates and said mobile chip maker Qualcomm would buy a minority stake as part of a research partnership.Alcatel CEO says Qualcomm deal may lead to others PARIS, July 30 Alcatel Lucent's joint venture with Qualcomm could be the first of several deals aimed at boosting the French telecom-equipment maker's footprint in fast-growing technologies, Alcatel's chief executive said on Tuesday.   
ROK,Rockwell Automation posts rise in quarterly profitRockwell Automation profit jumps past Wall Street viewsUPDATE 2-Rockwell Automation profit jumps past Wall Street views July 30 Rockwell Automation Inc, which makes systems that help factories run more smoothly, posted a quarterly profit well above analysts' forecasts on Tuesday, helped by sales increases in most of its geographic regions.  UPDATE 2-Rockwell Automation profit jumps past Wall Street views July 30 Rockwell Automation Inc, which makes systems that help factories run more smoothly, posted a quarterly profit well above analysts' forecasts on Tuesday, helped by sales increases in most of its geographic regions. Rockwell Automation Inc , which makes systems that help factories run more smoothly, posted a quarterly profit well above analyst forecasts on Tuesday, helped by sales increases in most of its geographic regions.UPDATE 2-Rockwell Automation profit jumps past Wall Street views July 30 Rockwell Automation Inc, which makes systems that help factories run more smoothly, posted a quarterly profit well above analysts' forecasts on Tuesday, helped by sales increases in most of its geographic regions.   Rockwell Automation profit jumps past Wall Street viewsUPDATE 2-Rockwell Automation profit jumps past Wall Street views July 30 Rockwell Automation Inc, which makes systems that help factories run more smoothly, posted a quarterly profit well above analysts' forecasts on Tuesday, helped by sales increases in most of its geographic regions.  UPDATE 2-Rockwell Automation profit jumps past Wall Street views July 30 Rockwell Automation Inc, which makes systems that help factories run more smoothly, posted a quarterly profit well above analysts' forecasts on Tuesday, helped by sales increases in most of its geographic regions. Rockwell Automation Inc , which makes systems that help factories run more smoothly, posted a quarterly profit well above analyst forecasts on Tuesday, helped by sales increases in most of its geographic regions.UPDATE 2-Rockwell Automation profit jumps past Wall Street views July 30 Rockwell Automation Inc, which makes systems that help factories run more smoothly, posted a quarterly profit well above analysts' forecasts on Tuesday, helped by sales increases in most of its geographic regions.  July 30 Rockwell Automation Inc, which makes systems that help factories run more smoothly, posted higher quarterly profit on Tuesday, helped by sales increases in most of its geographic regions.Rockwell Automation profit jumps past Wall Street viewsUPDATE 2-Rockwell Automation profit jumps past Wall Street views July 30 Rockwell Automation Inc, which makes systems that help factories run more smoothly, posted a quarterly profit well above analysts' forecasts on Tuesday, helped by sales increases in most of its geographic regions.  UPDATE 2-Rockwell Automation profit jumps past Wall Street views July 30 Rockwell Automation Inc, which makes systems that help factories run more smoothly, posted a quarterly profit well above analysts' forecasts on Tuesday, helped by sales increases in most of its geographic regions. Rockwell Automation Inc , which makes systems that help factories run more smoothly, posted a quarterly profit well above analyst forecasts on Tuesday, helped by sales increases in most of its geographic regions.UPDATE 2-Rockwell Automation profit jumps past Wall Street views July 30 Rockwell Automation Inc, which makes systems that help factories run more smoothly, posted a quarterly profit well above analysts' forecasts on Tuesday, helped by sales increases in most of its geographic regions.   
SYMC,Symantec reports higher quarterly revenueUPDATE 2-Symantec gains as hacking worries bring in more business July 30 Symantec Corp, the maker of Norton anti-virus software, posted better-than-expected quarterly results as customers used more of its security products in the wake of a series of hacking attacks, sending the company's shares up 4 percent.  UPDATE 2-Symantec gains as hacking worries bring in more business July 30 Symantec Corp, the maker of Norton anti-virus software, posted better-than-expected quarterly results as customers used more of its security products in the wake of a series of hacking attacks, sending the company's shares up 4 percent. July 30 Symantec Corp, the maker of Norton anti-virus software, reported higher quarterly revenue as more customers used its products for network security and data storage.UPDATE 2-Symantec gains as hacking worries bring in more business July 30 Symantec Corp, the maker of Norton anti-virus software, posted better-than-expected quarterly results as customers used more of its security products in the wake of a series of hacking attacks, sending the company's shares up 4 percent.  
MOS,REFILE-US STOCKS-Futures tick higher before data, Fed in focusUS STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.    US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.     US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.    US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.    * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.    US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.      US STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.    US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.     US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.    US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.    * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.    US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.     * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Futures tick higher ahead of data, Fed in focusUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.    US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.     US STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.    US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.    * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall Street rises on earnings; potash cos downUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.    US STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   * Mosaic, Potash Corp tumble after Russia quits top potash cartelUS STOCKS-Wall St rises on earnings; potash selloff reins in S&P;REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.   REFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  * Mosaic, Potash Corp sink after Russia quits top potash cartelREFILE-US STOCKS-Dow, S&P; 500 dip as materials, energy shares fallPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.  Potash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it. * Mosaic, Potash Corp sink after Russia quits top potash cartelPotash sector rocked as Russia's Uralkali quits cartel MOSCOW Russia's Uralkali   quit one of the world's two big potash cartels on Tuesday, heralding a price war for the key crop nutrient and pummeling the shares of companies that produce it.      
DIS,Disney, Weinstein to adapt 'Artemis Fowl' book series into film LOS ANGELES, July 29 Young adult fantasy book series "Artemis Fowl" about a 12-year-old millionaire criminal mastermind will be adapted into a feature film, Walt Disney Studios and the Weinstein Company said on Monday. 
VZ,Telus challenges Ottawa's wireless policy in court TORONTO, July 30 The battle between Canada's three large wireless carriers and the Canadian government escalated on Monday with one of the incumbents, Telus Corp , taking the government to court over a recent decision over the transfer of spectrum licenses. 
WMT,Wal-Mart, Google, others back U.S. bill to fight 'patent trolls' WASHINGTON, July 30 Dozens of major U.S. companies, including Morgan Stanley, Google, Wal-Mart and Dell, on Tuesday urged lawmakers to pass bills that they said would protect new products against "extortive demands" on patents. 
WU,UPDATE 3-Western Union profit beats as lower fees boost transfers * Shares jump 9.5 pct to highest in almost a year   (Adds CFO comments) 
WYNN,Macau mogul hopes dinosaurs trump volcanoes in new casino resort MACAU, July 31 Macau tycoon David Chow is ripping up the fake volcano and Roman amphitheatre that were the show pieces of a failed theme park he built in the Chinese gaming enclave seven years ago. 
YHOO,UPDATE 1-Accused SAC Capital tipster arrested in CaliforniaUPDATE 2-Accused tipper to SAC hedge fund arrested in insider-trading probe July 30 A securities analyst accused of leaking secret information in 2009 about a potential partnership between Yahoo and Microsoft to an SAC Capital Advisors hedge fund manager and other traders was arrested and charged in California, prosecutors said on Tuesday.  UPDATE 2-Accused tipper to SAC hedge fund arrested in insider-trading probe July 30 A securities analyst accused of leaking secret information in 2009 about a potential partnership between Yahoo and Microsoft to an SAC Capital Advisors hedge fund manager and other traders was arrested and charged in California, prosecutors said on Tuesday. July 30 A securities analyst who passed non-public information about Yahoo and Microsoft  to a portfolio manager at Steven A. Cohen's hedge fund SAC Capital Advisors was arrested in California, federal prosecutors said on Tuesday.UPDATE 2-Accused tipper to SAC hedge fund arrested in insider-trading probe July 30 A securities analyst accused of leaking secret information in 2009 about a potential partnership between Yahoo and Microsoft to an SAC Capital Advisors hedge fund manager and other traders was arrested and charged in California, prosecutors said on Tuesday.  
